1-12 of 12
Carlos García-Echeverría
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models

Maysoun Shomali, Jane Cheng, Fangxian Sun, Malvika Koundinya, Zhuyan Guo, Andrew T. Hebert, Jessica McManus, Mikhail N. Levit, Dietmar Hoffmann, Albane Courjaud, Rosalia Arrebola, Hui Cao, Jack Pollard, Joon Sang Lee, Laurent Besret, Anne Caron, Dinesh S. Bangari, Pierre-Yves Abecassis, Laurent Schio, Youssef El-Ahmad, Frank Halley, Michel Tabart, Victor Certal, Fabienne Thompson, Gary McCort, Bruno Filoche-Rommé, Hong Cheng, Carlos Garcia-Echeverria, Laurent Debussche, Monsif Bouaboula
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (2): 250–262.
https://doi.org/10.1158/1535-7163.MCT-20-0390
Published: 05 February 2021
View article titled, SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Open the PDF for SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor

Hélène Bonnevaux, Olivier Lemaitre, Loic Vincent, Mikhail N. Levit, Fanny Windenberger, Frank Halley, Cécile Delorme, Christoph Lengauer, Carlos Garcia-Echeverria, Angela Virone-Oddos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (7): 1460–1471.
https://doi.org/10.1158/1535-7163.MCT-15-0496
Published: 05 July 2016
View article titled, Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/<em>BRAF</em>-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor
Open the PDF for Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/<em>BRAF</em>-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor in another window
Includes: Supplementary data
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View article titled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Abstract B158: Transcriptional profile of NAMPTi unveils modulation of Tankyrase and Wnt/B-catenin pathway.

Maysoun Shomali, Patrick McGlynn, Dmitri Wiederchain, Paul August, Francisco Adrian, Carlos Garcia-Echeverria, Joachim Theilhaber, Monsif Bouaboula
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B158.
https://doi.org/10.1158/1535-7163.TARG-13-B158
Published: 01 November 2013
View article titled, Abstract B158: Transcriptional profile of NAMPTi unveils modulation of Tankyrase and Wnt/B-catenin pathway.
Journal Articles

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

Saskia M. Brachmann, Julia Kleylein-Sohn, Swann Gaulis, Audrey Kauffmann, Marcel J.J. Blommers, Malika Kazic-Legueux, Laurent Laborde, Marc Hattenberger, Fabian Stauffer, Juliane Vaxelaire, Vincent Romanet, Chrystèle Henry, Masato Murakami, Daniel Alexander Guthy, Dario Sterker, Sebastian Bergling, Christopher Wilson, Thomas Brümmendorf, Christine Fritsch, Carlos Garcia-Echeverria, William R. Sellers, Francesco Hofmann, Sauveur-Michel Maira
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1747–1757.
https://doi.org/10.1158/1535-7163.MCT-11-1021
Published: 08 August 2012
View article titled, Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Open the PDF for Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations in another window
Includes: Supplementary data
Journal Articles

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Matthew Burger, Mark Knapp, Dario Sterker, Christian Schnell, Daniel Guthy, Tobi Nagel, Marion Wiesmann, Saskia Brachmann, Christine Fritsch, Marion Dorsch, Patrick Chène, Kevin Shoemaker, Alain De Pover, Daniel Menezes, Georg Martiny-Baron, Doriano Fabbro, Christopher J. Wilson, Robert Schlegel, Francesco Hofmann, Carlos García-Echeverría, William R. Sellers, Charles F. Voliva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (2): 317–328.
https://doi.org/10.1158/1535-7163.MCT-11-0474
Published: 08 February 2012
View article titled, Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Open the PDF for Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor in another window
Includes: Supplementary data
Journal Articles

Abstract B76: In vitro screen to identify ALK mutations conferring crizotinib resistance.

Jean-Paul Nicolas, Laurent Dassencourt, Francoise Herve, Meredith Wolfrom, Amanda Lennon, Laure Delarbre, Dietmar Hoffmann, Vincent Leroy, Loreley Calvet, Carlos Garcia-Echeverria, Iris Valtingojer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B76.
https://doi.org/10.1158/1535-7163.TARG-11-B76
Published: 12 November 2011
View article titled, Abstract B76: In vitro screen to identify ALK mutations conferring crizotinib resistance.
Journal Articles

Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800

Andrew J. Massey, Joseph Schoepfer, Paul A. Brough, Josef Brueggen, Patrick Chène, Martin J. Drysdale, Ulrike Pfaar, Thomas Radimerski, Stephan Ruetz, Alain Schweitzer, Mike Wood, Carlos Garcia-Echeverria, Michael Rugaard Jensen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (4): 906–919.
https://doi.org/10.1158/1535-7163.MCT-10-0055
Published: 07 April 2010
View article titled, Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800
Open the PDF for Preclinical Antitumor Activity of the Orally Available Heat Shock Protein 90 Inhibitor NVP-BEP800 in another window
Includes: Supplementary data
Journal Articles

Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1

Sunil Upadhyay, Warren C. Fiskus, Rekha Rao, Atul Joshi, Sanjay Koul, Ramesh Balusu, Uma Mudunuru, Kathleen M. Buckley, Cornelia Quadt, Peter Atadja, Carlos Garcia‐Echeverria, Kapil N. Bhalla
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C196.
https://doi.org/10.1158/1535-7163.TARG-09-C196
Published: 10 December 2009
View article titled, Abstract C196: Co‐treatment with NVP‐BEZ235 and heat shock protein (hsp) 90 or pan‐deacetylase (DAC) inhibitor is synergistically active against non‐small cell lung cancer (NSCLC) cells with mutant RAS and LKB1
Journal Articles

Abstract B20: In vitro and in vivo antitumor activities of the dual PI3K/mTor inhibitor NVP‐BEZ235. Implications for patient stratification strategies

Michel Maira, Saskia Brachmann, Christine Fritsch, Irmgard Hofmann, Christian Schnell, Carlos Garcia‐Echeverria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B20.
https://doi.org/10.1158/1535-7163.TARG-09-B20
Published: 10 December 2009
View article titled, Abstract B20: <em>In vitro</em> and <em>in vivo</em> antitumor activities of the dual PI3K/mTor inhibitor NVP‐BEZ235. Implications for patient stratification strategies
Journal Articles

Inhibition of PI3 kinase by NVP-BEZ235 suppresses the PI3K/Akt/mTOR pathway and is growth inhibitory in human orthotopic primary pancreatic cancer xenografts

pinjiang cao, Saveur-Michel Maira, Carlos Garcia-Echeverria, David Hedley
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C195.
Published: 01 November 2007
View article titled, Inhibition of PI3 kinase by NVP-BEZ235 suppresses the PI3K/Akt/mTOR pathway and is growth inhibitory in human orthotopic primary pancreatic cancer xenografts
Journal Articles

NVP-AUY922: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy

Michael Rugaard Jensen, Joseph Schoepfer, Thomas Radimersky, Andrew Massey, Josef Brueggen, Alain Schweitzer, Ulrike Pfaar, Stephan Ruetz, Chantal Guy, Alan Buckler, Christian Schnell, Robert Cozens, Paul Brough, Martin Drysdale, Cornelia Quadt, Carlos Garcia-Echeverria, Patrick Chene
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B279.
Published: 01 November 2007
View article titled, NVP-AUY922: A novel small molecule HSP90 inhibitor with potent <em>in vivo</em> antitumor efficacy